摘要:
Objective To observe the effects of Xintongtai on cardiovascular remodeling in rats with coro-nary heart disease and illustrate the therapeutic mechanisms from renin-angiotensin-aldosterone system (RAAS). Methods 17 rats as the normal group were randomly selected from 95 SD rats, and the rest, 78 rats were used for coronary heart disease rat models which were established by high fat diets and intraperitoneal injection of Pituitrin. Then the successful model rats were randomly divided into five groups: the model group, low, middle, high dosages of Xintongtai groups and Catopril group. Rats in medication groups were given drug once daily for 28 d, and the normal group and model group were supplied equally volume of distilled water. The pathological changes of rats were measured by HE staining method. The contents of plasma renin activity (PRA), angiotensin (Ang Ⅱ), aldosterone (ALD) in rats were determined. Results After treatment for 4 weeks, the cardiac index, left ventricular mass index and right ventricular mass index in the medication groups were lower than those in the model group; the walls of the coronary arteries in medication groups were thinner than the model group, and the wall thickness/lumen diameter, wall area/ lumen area of the coronary arteries reduced; the levels of PRA, AngⅡ, ALD reduced (all P0.05). Conclusion Xintongtai could adjust renin-angiotensin-aldosterone system and display or reverse the cardiovascular remodeling, which improve myocardial blood flow and cardiac function of the rats with coronary heart disease. The effect of middle and high dose of Xintongtai groups is better than the low dose group.%目的 从肾素-血管紧张素-醛固酮系统切入,探讨心痛泰对冠心病血管重塑的调控作用.方法 将95只SD大鼠随机抽取17只为正常组,其余78只采用喂饲高脂饲料并腹腔注射垂体后叶素的方法制备冠心病大鼠模型.将造模成功的大鼠随机分为模型组,心痛泰低、中、高剂量组和卡托普利组.各组分别予相应的药物灌胃,正常组和模型组以同等体积的蒸馏水灌胃,每日1次,连续28 d.采用HE染色观察大鼠冠状动脉病理变化,ELISA法检测大鼠血浆肾素(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)的含量.结果 治疗4周后,与冠心病模型组比较,心痛泰低、中、高剂量组和卡托普利组心脏指数、左心室质量指数、右心室质量指数降低,冠状动脉管壁变薄,管壁厚度/管腔直径、管壁面积/管腔面积降低,血浆PRA、AngⅡ、ALD水平下降(P0.05).结论 心痛泰可调节肾素-血管紧张素-醛固酮系统,延缓甚至逆转心血管重构,从而改善冠心病大鼠心肌供血和心功能,且心痛泰中、高剂量组疗效优于低剂量组.